SIMPONI ARIA®
(golimumab)
SIMPONI ARIA® (golimumab)
SIMPONI ARIA - pivotal clinical trial publications
Ankylosing spondylitis (AS)
GO-ALIVE
Deodhar A, Reveille J, Harrison D et al. Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol. 2018;45(3):341-348.
Polyarticular juvenile idiopathic arthritis (pJIA)
GO-VIVA
Ruperto N, Brunner H, Pacheco-Tena C et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis [published online ahead of October 2, 2021]. Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507 .
Psoriatic arthritis (PsA)
GO-VIBRANT
Kavanaugh A, Husni M, Harrison D et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis results through week twenty-four of the GO-VIBRANT study. Arthritis Rheum. 2017;69(11):2151-2161.
Rheumatoid arthritis (RA)
GO-FURTHER
Weinblatt M, Bingham C, Mendelsohn A et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013;72(3):381-389.